7.4 Rearrangement Driven Oncogene Activation

Rearrangement Driven Oncogene Activation is the process by which chromosomal structural rearrangements—including translocations, inversions, and deletions—reposition a proto-oncogene relative to its normal genomic context, converting it into an active oncogene either by fusing it with another gene to create a novel chimeric protein or by placing it under the control of an inappropriately active regulatory element.

The General Principle

Positional Rather Than Sequence-Based Alteration

Unlike point mutations, which alter a gene's own coding sequence, rearrangement-driven activation typically leaves the oncogene's original sequence largely intact and instead changes its genomic neighbors, either its regulatory context or its physical fusion partner, achieving activation through a change in position rather than a change in the gene's own code.

Breakpoint Specificity

The functional consequence of a rearrangement depends critically on the precise location of the chromosomal breakpoints involved, since only breakpoints that place specific functional domains or regulatory sequences in a new, oncogenic configuration produce a transforming event, while breakpoints elsewhere are typically inconsequential.

Fusion Gene Formation

Chimeric Protein Generation

A chromosomal translocation can join coding sequences from two separate genes into a single, continuous reading frame, producing a fusion protein that combines functional domains from each parent gene, often resulting in a chimeric protein with constitutive activity absent from either original protein.

Functional Domain Combination

The oncogenic potential of a fusion protein commonly arises from the juxtaposition of a dimerization or oligomerization domain from one gene partner with the catalytic domain of a kinase from the other, forcing continuous self-association and constitutive activation of the kinase in the absence of its normal regulatory signal.

Regulatory Juxtaposition

Promoter and Enhancer Relocation

A chromosomal rearrangement can move a proto-oncogene's coding sequence next to the highly active regulatory elements of an unrelated, strongly transcribed gene, driving inappropriate overexpression of the otherwise structurally normal oncogene protein.

Loss of Native Regulatory Control

Rearrangement can simultaneously separate a proto-oncogene from its own native regulatory sequences, removing the normal constraints on its expression and compounding the effect of any newly acquired, more permissive regulatory context.

Mechanisms Generating Rearrangements

DNA Double-Strand Break Repair Errors

Chromosomal rearrangements commonly originate from errors occurring during the repair of DNA double-strand breaks, when segments from different chromosomal locations are incorrectly rejoined, a process that can be promoted by repetitive DNA sequences that predispose specific genomic regions to recurrent breakage and rearrangement.

Recurrent, Tumor-Type Specific Events

Certain rearrangements recur with high frequency in specific cancer types, reflecting both the physical proximity of the involved genomic regions within the nucleus and strong selective advantage conferred by the resulting oncogenic fusion or overexpression, making these rearrangements characteristic molecular features of the tumors in which they arise.

Functional and Clinical Consequences

Constitutive Signaling from Fusion Products

Cells carrying an oncogenic fusion protein typically display continuous activation of the associated signaling pathway, driving proliferation and survival independent of the normal upstream regulatory signals required by the unrearranged gene.

Diagnostic and Therapeutic Utility

Because rearrangement-driven oncogenes often produce a structurally unique fusion protein not present in normal cells, they serve as highly specific diagnostic markers and, in several cancers, as direct targets for therapies designed to selectively inhibit the fusion protein's aberrant activity.